The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has taken a significant step forward in the approval process for Moderna’s mRNA-based flu vaccine, mFlusiva. On Thursday, the panel of nine independent experts voted unanimously to endorse the vaccine for individuals aged 50 and older, concluding that the potential benefits outweigh the associated risks. This recommendation marks a pivotal moment in the ongoing effort to expand the range of flu prevention options available to the American public, particularly for older adults who are disproportionately affected by severe flu complications.
The decision comes amid a complex regulatory landscape shaped by recent controversies surrounding the vaccine’s initial submission. Earlier this year, the FDA faced internal conflict regarding Moderna’s application, with a top agency official temporarily blocking the review due to concerns over how the company compared its vaccine to existing flu shots. Specifically, the official argued that Moderna should have tested its vaccine against a high-dose flu vaccine recommended for seniors rather than a standard-dose version. This disagreement sparked a public dispute between the FDA and Moderna, highlighting the heightened scrutiny of vaccine approvals under Health Secretary Robert F. Kennedy Jr., who has expressed skepticism toward mRNA technology.
Following the controversy, the FDA reversed its stance and accepted Moderna’s application, acknowledging that the company had previously received approval for its trial design. During the recent advisory meeting, the panel reviewed extensive data from multiple studies, including a large-scale trial involving 40,000 participants aged 50 and older. The results showed that Moderna’s vaccine reduced flu cases by approximately 27% compared to a standard-dose vaccine. Additionally, a smaller study conducted on older adults demonstrated that the mRNA vaccine generated comparable levels of protective antibodies to a high-dose flu shot, further supporting its efficacy.
While the panel endorsed the vaccine for both adults aged 50–64 and those 65 and older, it emphasized the need for continued monitoring and additional trials, particularly for the older demographic. The FDA is expected to follow the advisory committee’s recommendation, though the final decision will depend on the agency’s evaluation of the data and its broader policy considerations. The vaccine’s approval would represent a groundbreaking milestone, as it would be the first mRNA-based flu vaccine globally, leveraging the rapid development capabilities of mRNA technology to potentially respond more swiftly to evolving viral strains.
Public health officials have long sought alternatives to traditional flu vaccines, which require months of preparation and may not fully align with circulating strains. mRNA vaccines, by contrast, can be designed and manufactured more quickly, allowing for quicker updates to match the latest flu variants. This flexibility is especially critical given the unpredictable nature of influenza, which can mutate rapidly and pose significant threats to vulnerable populations. Experts argue that the adoption of mRNA flu vaccines could enhance global preparedness for future pandemics and improve overall seasonal flu control.
The path to widespread availability, however, remains uncertain. Despite the advisory panel’s endorsement, the vaccine must still receive formal approval from the FDA and subsequent recommendations from the Centers for Disease Control and Prevention (CDC). Currently, the CDC’s advisory committee has been unable to convene due to a court order, delaying the final steps in the approval process. Moreover, the Department of Health and Human Services, under the leadership of Health Secretary Robert F. Kennedy Jr., has shown resistance to expanding the use of mRNA technology, despite its success in combating the COVID-19 pandemic.
As the situation unfolds, stakeholders—including healthcare providers, public health agencies, and pharmaceutical companies—will continue to monitor developments closely. The outcome of the FDA’s final decision will not only determine the fate of Moderna’s flu vaccine but also influence the trajectory of mRNA technology in the broader field of vaccinology. With the upcoming flu season approaching, the urgency for a reliable and adaptable vaccine solution has never been greater.
8 reports
STAT NewsIndependentCenterFactual 90Objective 9515 days agoAn FDA advisory panel has endorsed Moderna's mRNA flu vaccine after it faced controversy earlier this year when a top agency official initially resisted considering it for review. The panel voted unanimously that the benefits of the vaccine outweigh the risks for adults aged 50 to 64 and those 65 and older. The FDA is expected to make a decision soon, with staff presentations suggesting the vaccine could be licensed through a traditional pathway for the younger group and an accelerated pathway for the older group. A former FDA employee who now works for Moderna commented on the situation.
Bias read (Center): The article presents the facts of the FDA advisory panel's endorsement of Moderna's vaccine without overtly favoring any side. It mentions the controversy surrounding the vaccine and includes perspectives from multiple stakeholders, including a former FDA employee now working for Moderna. There is a
Why these scores (Factual 90 · Objective 95): The article accurately details the FDA advisory panel's endorsement of Moderna's mRNA flu vaccine, noting the previous controversy and the voting outcome. It presents the information in a balanced and objective manner.
The Washington TimesParty-alignedCenterFactual 90Objective 9515 days agoThe FDA advisory committee is considering approval of Moderna's first mRNA-based flu vaccine, mFlusiva, for individuals aged 50 and older. The vaccine showed a 27% reduction in flu cases compared to a commonly used alternative in a study involving 40,000 participants. The FDA has released a positive review of the data with no safety concerns noted. Moderna seeks full approval for the 50–64 age group and conditional authorization for those 65 and older during further testing.
Bias read (Center): The article presents factual information about the development and evaluation of a new medical technology without overtly favoring any political perspective. It focuses on scientific and regulatory processes rather than ideological arguments.
Why these scores (Factual 90 · Objective 95): The article accurately describes the FDA panel considering Moderna's mRNA flu vaccine, mentioning the study results and the previous controversy involving an FDA official. It presents information objectively without bias.
The HillIndependentCenterFactual 85Objective 9015 days agoThe FDA’s independent vaccine advisory panel voted unanimously 9-0 that the benefits of Moderna’s mFlusiva flu shot outweigh the risks for individuals aged 50 to 64 and those 65 and older.
Bias read (Center): The article presents a factual summary of the FDA panel's decision without apparent bias. It does not include subjective language, one-sided sourcing, or editorializing. The content focuses on the procedural outcome of the vote rather than taking a stance on the vaccine itself.
Why these scores (Factual 85 · Objective 90): The article states the FDA panel's unanimous recommendation for Moderna's vaccine for individuals aged 50 and older. It is concise and factual, though it lacks some contextual details present in other articles.
The HillIndependentCenterFactual 85Objective 9015 days ago FDA panel recommends mRNA flu vaccine for older adultsAn FDA advisory panel has recommended Moderna’s mRNA-based flu vaccine, mFlusiva, for approval for individuals aged 50 to 64 and those 65 and older. The panel voted unanimously 9-0, concluding that the benefits of the vaccine outweigh the risks.
Bias read (Center): The article presents factual information about an FDA recommendation without apparent ideological framing or biased language. It focuses on the procedural outcome of the vote and does not take a stance on the vaccine itself or related policy debates.
Why these scores (Factual 85 · Objective 90): The article accurately reports the FDA panel's recommendation for Moderna's mRNA-based vaccine for older adults. It maintains a neutral tone and provides relevant facts about the vaccine's potential impact.
NBC NewsIndependentCenterFactual 85Objective 7515 days agoAn FDA advisory panel unanimously recommended the approval of Moderna’s mRNA-based flu shot for older adults. If approved, it would be the first mRNA flu shot globally. The vaccine showed 27% greater effectiveness compared to traditional flu shots in late-stage trials. However, challenges remain regarding its availability this fall due to pending FDA approval and CDC recommendation. The CDC’s advisory committee has been prevented from meeting by a federal court order. Additionally, the Department of Health and Human Services, led by Secretary Robert F. Kennedy Jr., has expressed skepticism and
Bias read (Center): The article presents factual information about the FDA panel's recommendation, clinical trial results, and procedural hurdles without overtly favoring any political perspective. It includes context about HHS's stance but does so neutrally, without evaluative language.
Why these scores (Factual 85 · Objective 75): The article provides accurate details about the FDA panel's recommendation and includes relevant context about the vaccine's effectiveness and regulatory hurdles. However, the mention of HHS being 'hostile' to mRNA technology and RFK Jr.'s statements may introduce subjective interpretation rather th
The HillIndependentCenterFactual 75Objective 8516 days ago FDA vaccine panel set to review Moderna mRNA flu shotThe FDA's vaccine advisory panel is set to review Moderna's mRNA-based flu vaccine candidate. The article mentions that the panel appears open to the candidate ahead of a key meeting.
Bias read (Center): The article provides a factual summary of an upcoming FDA review without apparent ideological framing or biased language. It does not take a stance on the vaccine's merits or the panel's potential decision.
Why these scores (Factual 75 · Objective 85): The article discusses the FDA panel reviewing Moderna's mRNA flu shot and notes the potential for approval. While it is factually sound, it lacks specific details about the vaccine's performance or the review process.
NPR NewsIndependentCenterFactual 70Objective 8515 days agoA key FDA committee has unanimously recommended Moderna's new mRNA influenza vaccine for adults aged 50 and older.
Bias read (Center): The article reports on a unanimous recommendation by an FDA committee regarding a medical product. There is no discernible political framing, slant, or biased language. The content is purely factual and focuses on the approval process without taking a stance or emphasizing any particular perspective
Why these scores (Factual 70 · Objective 85): The article mentions the FDA committee recommending Moderna's vaccine for adults 50 and over, which aligns with the primary document's context. However, it lacks specific details about the vaccine's mRNA technology or the FDA's review process, making it less detailed than some other sources. The ton
STAT NewsIndependentCenterFactual 50Objective 6015 days ago STAT+: Pharmalittle: We’re reading about an FDA review of Moderna’s flu shot, J&J’s focus on cancer, and moreThe article discusses several pharmaceutical industry updates, including an FDA review of Moderna's flu shot, Johnson & Johnson's decision to focus on cancer research rather than entering the obesity market, and other related developments.
Bias read (Center): The article presents factual updates on pharmaceutical companies without overtly favoring any political perspective. It reports on business decisions and regulatory reviews in a neutral tone.
Why these scores (Factual 50 · Objective 60): The article contains irrelevant content like personal musings and unrelated news items, which detract from its factual accuracy regarding the FDA's review of Moderna's vaccine. It does mention the FDA approving GSK's antibiotic, which is unrelated to the main topic.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
United States
